| Cat.No. | Name | Information |
|---|---|---|
| M9872 | BS3 (bis(sulfosuccinimidyl)suberate) | BS3 (bis(sulfosuccinimidyl)suberate) is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). |
| M25138 | Pivekimab sunirine | Pivekimab sunirine (IMGN 632) is an antibody-drug conjugate (ADC) targeting CD123. Pivekimab sunirine comprises a high-affinity CD123 antibody, cleavable linker, and an indolinobenzodiazepine pseudodimer (IGN) payload. Pivekimab sunirine can be used for research of hematological malignancies. |
| M25118 | Farletuzumab ecteribulin | Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a drug-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. |
| M25054 | Tusamitamab ravtansine | Tusamitamab ravtansine (SAR-408701) is a DM4 anti-CEACAM5 antibody-drug conjugate (ADC). Tusamitamab ravtansine is composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. |
| M25010 | Patritumab deruxtecan | Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity. |
| M24944 | Serclutamab talirine | Serclutamab talirine (ABBV-321) is an EGFR-targeted antibody-drug conjugate (ADC). Serclutamab talirine is consisted of an antibody (AM-1-ABT-806) directed against activated EGFR and a pyrrolobenzodiazepine (PBD) dimer. Serclutamab talirine shows potent antitumor activity. |
| M24847 | Iladatuzumab vedotin | Iladatuzumab vedotin (DCDS-0780A) is an antibody-drug conjugate (ADC) containing humanized IgG1 anti-human CD79B monoclonal antibody conjugated to MMAE via a protease labile linker. |
| M24839 | Loncastuximab tesirine | Loncastuximab tesirine is a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC). Once bound to CD19 on the cell membrane, loncastuximab tesirine is rapidly internalised and triggers cell death. Loncastuximab tesirin induces cell apoptosis, it can be used for the research of diffuse large B-cell lymphoma. |
| M24824 | Sirtratumab vedotin | Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker. |
| M24768 | Trastuzumab duocarmazine | Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas. |
| M24756 | Ladiratuzumab vedotin | Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer. |
| M24707 | Indusatumab vedotin | Indusatumab vedotin (MLN-0264; AKT-264) is an antibody-drug conjugate (ADC) consisting of the human anti-guanylate cyclase C (GCC) antibody linked to a microtubule-disruptor Monomethyl auristatin . Indusatumab vedotin has anti-proliferative effects on pancreas cancer cell lines. Indusatumab vedotin arrests cell cycle at G2/M phase, and induces apoptosis. |
| M24697 | Labetuzumab govitecan | Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer. |
| M24661 | Sofituzumab vedotin | Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer. |
| M24646 | Lifastuzumab vedotin | Lifastuzumab vedotin (DNIB0600A) is an antibody-drug conjugate (ADC) that comprises a humanized IgG1 anti-NaPi2b monoclonal antibody (MNIB2126A) and a potent antimitotic agent, monomethyl auristatin E (MMAE), which inhibits cell division by blocking the polymerization of tubulin. |
| M24619 | Enfortumab vedotin | Enfortumab vedotin is an anti-Nectin-4 antibody-drug conjugate for the management of urothelial carcinoma. |
| M24559 | Vorsetuzumab mafodotin | Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity. |
| M24536 | Moxetumomab pasudotox | Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 Fv and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
